Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation.

MLA

Huerta-García, Ana P., et al. “Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation.” Journal of Clinical Pharmacology, vol. 61, no. 8, Aug. 2021, pp. 1118–30. EBSCOhost, https://doi.org/10.1002/jcph.1837.

APA

Huerta-García, A. P., Rodríguez-Báez, A. S., Medellín-Garibay, S. E., Portales-Pérez, D. P., Martínez-Martínez, M. U., Abud-Mendoza, C., Herrera-Van Oostdam, D., Romano-Moreno, S., & Milán-Segovia, R. D. C. (2021). Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation. Journal of Clinical Pharmacology, 61(8), 1118–1130. https://doi.org/10.1002/jcph.1837

Chicago

Huerta-García, Ana P, Ana S Rodríguez-Báez, Susanna E Medellín-Garibay, Diana P Portales-Pérez, Marco U Martínez-Martínez, Carlos Abud-Mendoza, David Herrera-Van Oostdam, Silvia Romano-Moreno, and Rosa Del C Milán-Segovia. 2021. “Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation.” Journal of Clinical Pharmacology 61 (8): 1118–30. doi:10.1002/jcph.1837.